AEVLI
Explore app
RESEARCH PEPTIDE PROFILE
Experimental neuropeptide

DSIP

A historically studied “delta sleep-inducing peptide” whose name is more confident than the inconsistent human sleep evidence warrants.

AEVLI RESEARCHDSIPEDUCATIONAL PROFILE
Research context

This page summarizes published evidence and regulatory context. It does not provide sourcing, dosing, prescribing, reconstitution or administration instructions.

What is DSIP?

Delta sleep-inducing peptide (DSIP) is a small peptide investigated in human sleep research primarily in older, small studies.

Proposed mechanism

Its precise physiological role remains uncertain. Historical work explored sleep architecture and hypothalamic-pituitary-adrenal signalling.

What has been published?

Small double-blind and controlled human studies from the 1980s and early 1990s examined sleep and neuroendocrine effects.

Current human evidence

Results are inconsistent. A double-blind study in 16 chronic insomnia patients found some objective sleep measures favored DSIP, but investigators concluded short-term treatment was unlikely to have major therapeutic benefit.

Regulatory status

DSIP is not an FDA-approved insomnia medicine.

Possible areas of research interest

  • Sleep physiology
  • Neuropeptide biology
  • Circadian research
  • HPA-axis signalling

Important limitations

  • Human studies are small and old
  • Sleep outcomes are inconsistent
  • The peptide name can overstate certainty about physiological function
  • Modern large insomnia trials are lacking

References

AEVLI prioritizes primary publications and regulator materials over anecdotal claims.

Double-blind insomnia study — PubMedControlled human sleep study — PubMedHuman ACTH study — PubMed
← Research peptide library